Drug Trial Radar · NCT01412060
A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia
Last checked: Nov 20, 2026Latest source record: Jul 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
765
Actual
Start
Sep 27, 2011
Primary completion
Sep 3, 2014
Study completion Sep 3, 2014
Sponsor
- Lead sponsor
- Forest LaboratoriesAbbVie (ABBV)
- Sponsor type
- Industry
- Collaborators
- Gedeon Richter Ltd.
- First posted
- Aug 8, 2011
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study is to evaluate the efficacy and safety of cariprazine relative to placebo in the prevention of relapse of symptoms in participants with schizophrenia.
Conditions
- Schizophrenia
Interventions
PlaceboDrug
Placebo was supplied in capsules.
CariprazineDrug
Cariprazine was supplied as 1.5 mg capsules (batch numbers BN0009242 and BN00018595) and 3 mg capsules.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time From Baseline to the First Symptom Relapse During the Double-blind PhaseTime frame: Up to 34 Weeks and Bi-Weekly thereafter until Week 92
Locations
73 sites in 5 countries. Site status is shown where the registry gives one.
Forest Investigative Site 011
Little Rock, Arkansas
Forest Investigative Site 018
Cerritos, California
Forest Investigative Site 007
Costa Mesa, California
Forest Investigative Site 026
Culver City, California
Forest Investigative Site 008
Long Beach, California
Forest Investigative Site 002
Oceanside, California
Forest Investigative Site 019
Orange, California
Forest Investigative Site 001
Paramount, California
Forest Investigative Site 020
San Diego, California
Forest Investigative Site 005
Washington D.C., District of Columbia
Forest Investigative Site 024
Leesburg, Florida
Forest Investigative Site 017
Atlanta, Georgia
Forest Investigative Site 021
Chicago, Illinois
Forest Investigative Site 023
Baltimore, Maryland
Forest Investigative Site 010
Rockville, Maryland
Forest Investigative Site 003
Flowood, Mississippi
Forest Investigative Site 006
Creve Coeur, Missouri
Forest Investigative Site 014
St Louis, Missouri
Forest Investigative Site 012
Cedarhurst, New York
Forest Investigative Site 022
Dayton, Ohio
Forest Investigative Site 015
Austin, Texas
Forest Investigative Site 027
Austin, Texas
Forest Investigative Site 025
Dallas, Texas
Forest Investigative Site 013
Houston, Texas
Forest Investigative Site 009
Houston, Texas
Forest Investigative Site 305
Vijayawada, Andhra Pradesh, India
Forest Investigative Site 303
Ahmedabad, Gujarat, India
Forest Investigative Site 308
Ahmedabad, Gujarat, India
Forest Investigative Site 310
Ahmedabad, Gujarat, India
Forest Investigative Site 313
Mangalore, Karnataka, India
Forest Investigative Site 314
Manipal, Karnataka, India
Forest Investigative Site 301
Chhatrapati Sambhajinagar, Maharashtra, India
Forest Investigative Site 306
Kalyān, Maharashtra, India
Forest Investigative Site 311
Nashik, Maharashtra, India
Forest Investigative Site 317
Jaipur, Rajasthan, India
Forest Investigative Site 302
Jaipur, Rajasthan, India
Forest Investigative Site 312
Madurai, Tamil Nadu, India
Forest Investigative Site 309
Kanpur, Uttar Pradesh, India
Forest Investigative Site 304
Lucknow, Uttar Pradesh, India
Forest Investigative Site 307
Varanasi, Uttar Pradesh, India
Showing 40 of 73 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.